Skip to content

Developing a molecular patch for collagen VI-related muscular dystrophy

Professor Carsten Bonnemann and his colleagues from the National Institute of Health (US) aim to develop a new kind of molecular patch for Collagen VI-related muscular dystrophy that can be delivered using adeno-associated virus (AAV).
Details
Principal Investigator
Professor Carsten Bonnemann
Institute
National Institute of Health (US)
Official title
COL6A1 intron 11 pseudo-exon skipping using scAAV-delivered U7snRNA-driven splice modulation
Duration
2 years
Total cost
£75,000
Conditions
Bethlem myopathy Ullrich congenital muscular dystrophy (UCMD)
Year
2023

Background

Our genes are the instruction manuals to proteins. Proteins play a key role in all the tasks that keep our bodies working properly. For example, the collagen VI protein is part of the protective and supportive environment that surrounds muscle cells – called the extracellular matrix. Changes can happen to the instructions, which means proteins are made differently. These altered proteins can cause damage to the cells. When the collagen VI protein is changed, it can cause the environment outside of muscle cells to provide less support and protection. This can lead to muscle damage and cause congenital muscular dystrophies, such as Bethlem myopathy and Ullrich congenital muscular dystrophy (UCMD).

There are several genes involved in making the collagen VI protein. The process involves making a copy of the collagen VI genes (known as RNA), which are transported to the protein making machinery in the cell. Professor Bonnemann and team have identified a change to the COL6A1 gene (called the COL6A1 c.930+189C>T variant). This leads to the addition of an extra piece of genetic sequence to the copy of the COL6A1 gene (called a pseudoexon). The researchers have shown that the addition of this genetic sequence means the collagen VI protein causes damage to environment outside of the muscle cells, leading to a severe form of collagen VI-related muscular dystrophy.

Project aims

This project aims to develop a new molecular patch. Molecular patches are small molecules which mask specific genetic sequences, so that the sequence is ignored during protein production. Molecular patches are being investigated as part of an approach, known as exon skipping, to treat some muscle wasting and weakening conditions. This project will use molecular patches to skip over the extra genetic sequence (pseudoexon) caused by the COL6A1 gene change.

Once Professor Bonnemann’s team have identified a promising molecular patch, they will investigate how to deliver the potential treatment into the body. They will package the molecular patch into a virus, which is harmless and does not cause disease. The potential treatment will then be tested in models of the condition to see if it can reach the muscles and limit the damage to the environment outside of muscle cells.

Why is this research important?

The specific change to the COL6A1 gene causes a severe type of collagen VI-related muscular dystrophy. This project aims to find a way to slow the progression and potentially treat the condition. If the project shows positive results, the potential treatment could start to move towards testing in people in clinical trials. The molecular patch for collagen VI-related muscular dystrophy is very early in its development, but with further research could become a treatment for this condition.

We’ve already made great progress.

But there is still so much that needs to be done. Together, we can change the future of muscle wasting conditions. Join us. Today.